Master of Science / Department of Clinical Sciences / James K. Roush / The objective of this study was to evaluate the effects of intraarticular dextrose prolotherapy on osteoarthritis of the elbow or stifle in dogs. This was a randomized, double-blind, placebo controlled prospective trial of intraarticular dextrose prolotherapy given at 0 and 6 weeks for relief of osteoarthritis. Dogs with unilateral lameness were evaluated by orthopedic exam, visual lameness score, Canine Brief Pain Inventory (CBPI), goniometry, and by kinetic gait analysis at 0, 6 and 12 weeks. Joint radiographs were scored at 0 and 12 weeks. Ten client-owned dogs with naturally occurring osteoarthritis of the elbow or stifle were enrolled. Initial visual lameness, age, body weight, duration of lameness, and CBPI scores did not differ between groups. Change in CBPI PS score in the prolotherapy group from week 6-12 was significantly less improved than placebo with no other significant differences in CBPI Pain Severity (PS) or Pain Interference (PI) scores between groups. There were no significant differences for range of motion or radiographic scores between groups at any time. Kinetic forces improved in prolotherapy dogs, but were not significantly different between treatment groups at any time. There were no significant benefits of intraarticular dextrose prolotherapy for treatment of osteoarthritis of the elbow and stifle in dogs in this study. Larger enrollments and more stringent inclusion criteria should be considered in future evaluations of prolotherapy.

Significant cost and debilitation results from connective tissue injury and disease every year. Prolotherapy is an effective medical treatment used to increase joint stability. However, most associated studies are retrospective or case studies, rather than comprehensive laboratory investigation originating with the cellular response to exposure to the proliferant solutions. As a parallel consideration, nanoparticles are being investigated for use in drug delivery and heat shock treatment of cancerous tissue due to their unique structural and thermal properties. The phenomenal strength and stiffness of carbon nanoparticles have been used for commercial purposes in composite materials, but investigation of biomedical applications is still fairly nascent. In an attempt to develop a non-surgical approach to supporting and healing damaged ligaments and tendons resulting from injury or disease by combining prolotherapy and the use of nanoparticles, the author presents studies investigating the cellular response to proliferative therapy solution as well as tendon and ligament tissue's mechanical and cellular response to exposure to nanoparticles. In the prolotherapy solution cell studies, the results suggested that there is an optimal dosage of the proliferant for in vitro studies, different responses between cell types, and a dosage-dependent response in cell viability and collagen production to the solution P2G in preosteoblasts. In the nanoparticle studies, cell populations tolerated nanoparticles at the levels tested, tendon mechanical properties were increased (stiffness significantly so), and bright field and transmission electron microscopic histological images were taken of connective tissue and carbon nanohorn interactions. / Master of Science